5th ALS Drug Development Summit 2026 The Colonnade Hotel, Boston

Bolstering a Resurgence in Novel Approaches to Target Underlying Pathology, Address Disease Heterogeneity and Restore Hope in a More Transformative Wave of ALS and FTD Therapies.

Uniting ALS Biotech, Pharma and Academia to Accelerate the Next Generation of ALS and FTD Therapeutics.

Strategic moves across the sector-from Eli Lilly’s Alchemab-backed ALS expansion to BMS and insistro’s genetically driven collaboration and Clene Nanomedicine’s regulatory-stage program-underscore the ALS community’s continued commitment to advancing impactful therapies, even in the face of clinical setbacks.

With over 475 therapies in development, and 157 active or enrolling trials, and more than 350 companies actively working in ALS, and a global ALS market projected to grow from USD 667.3M in 2023 to USD 987.6M by 2030, confidence is returning. Learnings, fuelled by stronger mechanistic hypotheses, and more resilient translational strategies, spanning TDP 43 loss and gain of function biology, cryptic exon regulation, neuroinflammatory pathways, and human relevant iPSC and 3D models, the ALS community is leveraging these lessons to build smarter, more predictive programs.